Why Lung Cancer Treatment Varies
A lung cancer treatment plan is not the same for every patient. Even two people diagnosed with lung cancer at a similar time may receive very different recommendations based on the type and stage of their cancer, certain characteristics of their tumor, and their overall health.
Understanding what goes into a lung cancer treatment plan can help patients feel more informed about their care and the questions they may want to ask their oncology team.
Why Do Lung Cancer Treatments Differ Between Patients?
Lung cancer is not a single disease, and treatment decisions involve more than the diagnosis alone.
An oncology team considers several factors when recommending treatment, including the type of lung cancer, how far it has spread, whether certain biomarkers, including specific genetic mutations, are present, which treatments the patient has previously received, and the patient's overall health and treatment goals.
This means that a treatment recommended for one person may not be appropriate for another, even if both have been diagnosed with lung cancer.
How Does the Type of Lung Cancer Affect Treatment?
The two main types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Non-small cell lung cancer (NSCLC) is the more common type and includes subtypes such as adenocarcinoma and squamous cell carcinoma. Depending on the stage and other factors, treatment may involve surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, or a combination of approaches.
Small cell lung cancer (SCLC) generally grows and spreads more quickly. Treatment often involves systemic therapies, such as chemotherapy and immunotherapy, sometimes combined with radiation therapy.
Identifying the specific type of lung cancer is one of the first steps in determining an appropriate treatment approach.
Why Does the Stage of Lung Cancer Matter?
Cancer stage describes the extent of cancer in the body, including the size and location of the tumor and whether it has spread to lymph nodes or other organs.
For some patients with early-stage lung cancer, surgery or radiation therapy may be recommended with the goal of treating the cancer locally. Other treatments may also be recommended to reduce the risk of recurrence.
For patients with more advanced disease, treatment may focus on controlling cancer throughout the body, managing symptoms, and maintaining quality of life.
The stage of cancer helps guide treatment recommendations, but it is only one part of the decision-making process.
What Is Biomarker Testing, and How Can It Influence Treatment?
Biomarker testing looks for certain molecular characteristics of cancer cells that may help guide treatment decisions.
In some types of non-small cell lung cancer, testing may identify changes in genes such as EGFR, ALK, ROS1, or other biomarkers that can help determine whether targeted therapy may be an option.
Other tests, such as PD-L1 testing, may provide information that helps the oncology team consider immunotherapy.
Not every patient will have an actionable biomarker, and testing recommendations depend on the type and stage of lung cancer. However, when appropriate, biomarker testing can provide important information for developing an individualized treatment plan.
How Do Overall Health and Personal Preferences Affect Treatment?
Cancer treatment decisions also consider the person receiving care, not just the cancer itself.
A patient's overall health, other medical conditions, lung function, and ability to tolerate certain treatments may influence which options are recommended.
Personal preferences and treatment goals are also important. Patients may have questions about potential side effects, treatment schedules, daily activities, and how treatment could affect their quality of life.
Discussing these priorities with an oncology team supports shared decision-making and helps ensure the treatment plan reflects each patient's individual circumstances.
Can a Lung Cancer Treatment Plan Change Over Time?
Yes. A lung cancer treatment plan may change based on how the cancer responds, new test results, side effects, or changes in a patient's health.
For example, a treatment may be adjusted if it is not working as expected or if side effects become difficult to manage. In certain circumstances, additional biomarker testing may help identify other treatment options.
Regular communication and follow-up appointments allow the oncology team to evaluate progress and determine whether changes are needed.
What Questions Should You Ask About Your Lung Cancer Treatment Plan?
Understanding the reasons behind a treatment recommendation can help patients participate more confidently in decisions about their care.
Consider asking your oncology team:
- What type and stage of lung cancer do I have?
- Is biomarker testing recommended for my diagnosis?
- What treatment options are available, and why are you recommending this approach?
- What are the goals and potential side effects of treatment?
- How will we know whether my treatment is working?
- Are clinical trials an option for me?
Personalized Care Starts With Understanding Your Options
There is no single treatment plan that is right for everyone diagnosed with lung cancer. Advances in cancer research and treatment have expanded the options available to certain patients, allowing oncology teams to consider more characteristics of both the cancer and the individual.
Understanding the factors behind treatment recommendations and maintaining open communication with your care team can help you make informed decisions throughout your cancer care journey.